drugset / Trial / NCT00025415

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

NCT00025415

Phase 1 Completed 60 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have advanced cancer and liver dysfunction

Timeline

Start
2001-08
Primary completion
2005-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule Oral